Reported about 1 month ago
Three Motley Fool contributors recommend investing in Eli Lilly, Novo Nordisk, and Vertex Pharmaceuticals for September. Eli Lilly's growth is driven by the promising tirzepatide drug, while Novo Nordisk continues to excel in diabetes and weight loss treatments. Vertex Pharmaceuticals stands out for its successful cystic fibrosis therapy and innovative gene-editing treatments. Each of these stocks is considered a strong buy due to their significant growth potential in the healthcare sector.
Source: YAHOO